Sarepta Therapeutics, Inc.
SRPT
$105.56
-$2.11-1.96%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 52.97% | 48.45% | 49.98% | 43.83% | 33.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 52.97% | 48.45% | 49.98% | 43.83% | 33.26% |
| Cost of Revenue | 9.33% | -0.15% | -10.56% | -6.91% | 1.05% |
| Gross Profit | 261.01% | 742.24% | 1,124.58% | 520.45% | 356.47% |
| SG&A Expenses | 15.77% | 11.70% | 14.05% | 1.60% | 6.75% |
| Depreciation & Amortization | 54.27% | 163.28% | 236.69% | 177.59% | 118.35% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.43% | 3.66% | -3.05% | -4.16% | 2.85% |
| Operating Income | 181.43% | 120.29% | 107.45% | 83.86% | 50.05% |
| Income Before Tax | 150.14% | 119.55% | 107.03% | 103.10% | 24.62% |
| Income Tax Expenses | 60.81% | -74.03% | -34.13% | 2.83% | 17.40% |
| Earnings from Continuing Operations | 143.89% | 117.64% | 105.21% | 101.52% | 23.81% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 143.89% | 117.64% | 105.21% | 101.52% | 23.81% |
| EBIT | 181.43% | 120.29% | 107.45% | 83.86% | 50.05% |
| EBITDA | 214.49% | 133.64% | 116.67% | 90.28% | 54.80% |
| EPS Basic | 140.26% | 116.50% | 104.65% | 101.12% | 24.04% |
| Normalized Basic EPS | 182.45% | 122.32% | 109.71% | 86.61% | 56.51% |
| EPS Diluted | 138.99% | 115.86% | 104.30% | 100.83% | 23.82% |
| Normalized Diluted EPS | 174.33% | 121.28% | 109.12% | 86.14% | 56.34% |
| Average Basic Shares Outstanding | 5.80% | 6.77% | 5.31% | 4.01% | 2.63% |
| Average Diluted Shares Outstanding | 12.18% | 11.93% | 9.05% | 6.47% | 3.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
